This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents. Top assignee: Universitéde Montreal. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Eric Beaulieu: Innovator in Proliferative Disease Treatment
Introduction
Eric Beaulieu is a notable inventor based in Mercier, Canada. He has made significant contributions to the field of medicine, particularly in the treatment of proliferative diseases. With a total of 2 patents to his name, Beaulieu's work is recognized for its potential impact on healthcare.
Latest Patents
Among his latest patents, Beaulieu has developed Pyrido[3,2-d]pyrimidine compounds that are used for treating proliferative diseases. These compounds are particularly relevant for conditions associated with RAF and RAS gene mutations. The patents detail compounds, compositions, and their applications in treating such diseases, emphasizing the importance of these innovations in medical science.
Career Highlights
Beaulieu is affiliated with the Université de Montreal, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients suffering from complex diseases.
Collaborations
Throughout his career, Beaulieu has collaborated with esteemed colleagues, including Pierre Louis Beaulieu and Joanne Tan. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Eric Beaulieu's contributions to the field of medicine through his patents and research are commendable. His work in developing treatments for proliferative diseases showcases the vital role of inventors in advancing healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile